World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)
世界新兴病毒和虫媒病毒参考中心 (WRCEVA)
基本信息
- 批准号:9210602
- 负责人:
- 金额:$ 92.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-02-01 至 2021-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAntibodiesAntigenic DiversityAntigensArbovirusesArthropodsBiologicalBioterrorismChikungunya virusClinicalCollaborationsCollectionCommunitiesComplementary DNACoronaviridaeCoronavirusCryoelectron MicroscopyCulicidaeDatabasesDengueDiagnosisDiagnosticDisease OutbreaksEbola virusEcologyElectron MicroscopyEnsureEpidemiologyEvolutionFamilyFoundationsFundingGeneticGenetic DeterminismGenetic VariationGenomicsGenus PhlebovirusGoalsGrowthHantavirusHealthHemorrhageHumanImmune SeraIn VitroInfectionInstitutionInternationalInterventionLaboratoriesLocationMedicalMethodsNational Institute of Allergy and Infectious DiseaseNew YorkPathogenesisPatternPhenotypePhylogenetic AnalysisPlayPrincipal InvestigatorPublic HealthQuality ControlReagentRecording of previous eventsResearchResearch SupportRoleSamplingScientistSerologicalSevere Acute Respiratory SyndromeShipsSourceTaxonomyTexasTherapeuticTrainingUnited States National Institutes of HealthUniversitiesVaccine DesignVaccinesViralViral GenomeVirusVirus DiseasesYellow FeverZoonosesanthropogenesisbasebiodefensedeep sequencingeffective interventionfeedinghuman diseaseimprovedin vivonew technologynext generation sequencingnovelprogramspublic health relevancerepositorytherapeutic developmenttooltransmission processvaccine developmentvectorvector transmissionvirus identificationweapons
项目摘要
DESCRIPTION (provided by applicant): New and emerging viruses and arboviruses represent increasing threats to human health, yet their mechanisms of emergence remain poorly understood, and effective interventions are not available for most. Research on their ecology, evolution, epidemiology, emergence mechanisms, diagnostics, and development of vaccines and therapeutics remain critical public health needs. The World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) comprises a comprehensive, diverse collection of over 6,700 virus strains in 21 families, as well as antisera, antigens and other reagents to enable research worldwide. Approximately 400 new virus strains are added each year, and 1000 viruses and reagents are shipped annually. The WRCEVA also maintains broad expertise in both novel and traditional approaches to virus identification and characterization, and assists with outbreak diagnosis. This proposal seeks to continue these WRCEVA activities in support of NIH-funded and other research on emerging viruses worldwide through 5 Specific Aims: 1. Maintain a comprehensive set of emerging viruses, arboviruses and associated reagents to support research and surveillance. The virus collection as well as antigens, antibodies and other reagents will be continually enhanced to capitalize on new technology, and cDNA clones of selected strains will be added. NextGen sequencing-based quality control practices will be implemented to ensure strain accuracy/purity. 2. Discover, isolate and characterize newly acquired viruses by using electron microscopy, next generation sequencing, and serologic methods to determine relationships and taxonomic assignments, and to assess in vitro and in vivo host range. Clinical and field samples as well as viral isolates will be received for identification and characterization, and added to the repository. Critical phenotypes of newly discovered viruses and strains will be assessed by using in vitro and in vivo infections. 3. Perform sequencing and phylogenetic analyses of selected virus groups to determine evolutionary histories and emergence mechanisms, patterns of spread and infection, and to rapidly determine the sources of new outbreaks. Key virus strains will undergo genomic sequencing to generate databases that can be exploited for the rapid determination of new outbreak sources, including potential bioterrorism. 4. Characterize recently discovered mosquito-specific viruses (MSVs) and determine their evolutionary history, impact on the transmission of arboviruses, and genetic determinants of host range. Selected arbovirus taxa that include mosquito-specific viruses will be studied to understand the genetic basis of their host range restriction and assess their potential as tools to interfere with arbovirus transmission 5. Train scientists in the identification and characterization of emerging viruses and arboviruses.
To further enhance research efforts in the U.S. and worldwide as well as to leverage collaborations that feed our collections, basic training in virus identification and characterizaton will be provided to qualified scientists.
描述(由申请人提供):新出现的病毒和虫媒病毒对人类健康的威胁日益增加,但对其出现的机制仍知之甚少,大多数病毒和虫媒病毒缺乏有效的干预措施。对它们的生态学、进化、流行病学、出现机制、诊断以及疫苗和疗法的开发进行研究仍然是关键的公共卫生需求。世界新兴病毒和虫媒病毒参考中心(WRCEVA)包括21个家族的6,700多个病毒株的全面,多样化的收集,以及抗血清,抗原和其他试剂,以使全球研究成为可能。每年增加约400种新病毒株,每年运送1000种病毒和试剂。WRCEVA还在病毒识别和表征的新方法和传统方法方面拥有广泛的专业知识,并协助疫情诊断。该提案旨在通过5个具体目标继续这些WRCEVA活动,以支持NIH资助的和其他关于全球新兴病毒的研究:1。维护一整套新出现的病毒、虫媒病毒和相关试剂,以支持研究和监测。将继续加强病毒收集以及抗原、抗体和其他试剂,以利用新技术,并将增加选定毒株的cDNA克隆。 将实施基于NextGen测序的质量控制规范,以确保菌株准确度/纯度。2.通过使用电子显微镜、下一代测序和血清学方法发现、分离和表征新获得的病毒,以确定关系和分类分配,并评估体外和体内宿主范围。将接收临床和田间样本以及病毒分离株进行鉴定和表征,并添加到储存库中。新发现的病毒和菌株的关键表型将通过使用体外和体内感染进行评估。3.对选定的病毒群进行测序和系统发育分析,以确定进化历史和出现机制、传播和感染模式,并迅速确定新疫情的来源。将对关键病毒株进行基因组测序,以生成数据库,用于快速确定新的爆发源,包括潜在的生物恐怖主义。4.描述最近发现的蚊子特异性病毒(MSV),并确定它们的进化历史,对虫媒病毒传播的影响以及宿主范围的遗传决定因素。将研究包括蚊子特异性病毒在内的选定虫媒病毒分类群,以了解其宿主范围限制的遗传基础,并评估其作为干扰虫媒病毒传播工具的潜力5。培训科学家识别和描述新出现的病毒和虫媒病毒。
为了进一步加强美国和世界范围内的研究工作,并利用合作来充实我们的收藏,将向合格的科学家提供病毒识别和表征的基本培训。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Scott C Weaver其他文献
Scott C Weaver的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Scott C Weaver', 18)}}的其他基金
West African Center for Emerging Infectious Diseases
西非新发传染病中心
- 批准号:
10427336 - 财政年份:2020
- 资助金额:
$ 92.49万 - 项目类别:
West African Center for Emerging Infectious Diseases
西非新发传染病中心
- 批准号:
10187519 - 财政年份:2020
- 资助金额:
$ 92.49万 - 项目类别:
West African Center for Emerging Infectious Diseases
西非新发传染病中心
- 批准号:
10626824 - 财政年份:2020
- 资助金额:
$ 92.49万 - 项目类别:
West African Center for Emerging Infectious Diseases
西非新发传染病中心
- 批准号:
10468361 - 财政年份:2020
- 资助金额:
$ 92.49万 - 项目类别:
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)
世界新兴病毒和虫媒病毒参考中心 (WRCEVA)
- 批准号:
10598513 - 财政年份:2016
- 资助金额:
$ 92.49万 - 项目类别:
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)
世界新兴病毒和虫媒病毒参考中心 (WRCEVA)
- 批准号:
8999458 - 财政年份:2016
- 资助金额:
$ 92.49万 - 项目类别:
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)
世界新兴病毒和虫媒病毒参考中心 (WRCEVA)
- 批准号:
10170884 - 财政年份:2016
- 资助金额:
$ 92.49万 - 项目类别:
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)
世界新兴病毒和虫媒病毒参考中心 (WRCEVA)
- 批准号:
10391524 - 财政年份:2016
- 资助金额:
$ 92.49万 - 项目类别:
Trajectory of Vector-adaptive Chikungunya Virus Evolution
载体适应性基孔肯雅病毒的进化轨迹
- 批准号:
9009006 - 财政年份:2015
- 资助金额:
$ 92.49万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 92.49万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 92.49万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 92.49万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 92.49万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 92.49万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 92.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 92.49万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 92.49万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 92.49万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 92.49万 - 项目类别:














{{item.name}}会员




